other companies: Industrial approvals generally do not specify separate capacity of each and every formulation and pack. Details of production and sales turn over of formulation are not monitored in this Ministry.

(f) Both the companies referred to in befrs of the Sub-Committee of Drugs Priameters of Drug Policy of 1978.

Sub Committee of drugs price review Committee

2816. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 978 given in the Rajya Sabha on 25th November, 1985 and state:

(a) what are the names of the members of the Sub-Committee of Drugs Prices Review Committee constituted by Government along with department each represents;

(b) what role is being played by each member and how many of them are costing experts or qualified;

(c) whether it is a fact that the nominee of his Ministry is deciding authority both at Sub-Committee as well as at departmental level;

(d) if so, what are the details thereof;

(e) what are the reasons for not verifying the purchase or procured price of each bulk drug of each formulator and how far fixing the formulation price based on notified price helps the consumer to get the medicines at fair price; and

(f) what is the justification in not fixing the formulations prices based on purchase price of bulk drug?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Director (Cost), DICP. Member (Finance) BICP, nominees of this Departments and representatives of DGTD and DGHS are Members of the Sub-Committee of Drugs Prices Review Committee.

(b) The Member Secretary of the Sub-Committee is a qualified Cost Accountant. The other members have expertise in finance, pharmacy and production processes.

(c) No, ir. The decisions of the Sub-Committee are collective decisions.

(d) Does not arise.

(e) and (f) The formulation prices are fixed based on relevant factors including the notified prices, purchase prices and landed prices of bulk drugs.

Formulations containing pentothol sodium

2817. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 983 given in the Rajya Sabha on the 25th November, 1985 and state:

(a) whether it is a fact that Pentothol Sodium comes under Category III of DPCO, 1979;

(b) whether it is a fact that it goes into the production of Vitamin formulations;

(c) if so, what are the names of formulations being produced by Abbot containing Pentothol Sodium along with prices fixed for each pack and strength as well as their selling price of each product;

(d) whether it is a fact that Abbot was licensed to produce bulk drugs earlier to this licence;

(e) if so, what are the details thereof and whether that licence was implemented;

(f) if not, what are the reasons thereof;

(g) what are the details of exports of Rupees forty two lacs by Abbott in 1984 along with name of each formulation, composition, quantity and value of each; and

(h) what is the price fixed for Pentothol Sodium and whether it was based on Abbots cost of production?